Medtronic plc stock (IE00BTN1Y115): Global medical device leader with strong US presence

Medtronic plc, a pioneer in medical technology, continues to drive innovation in cardiovascular, diabetes, and neuromodulation devices, serving millions of patients worldwide with significant exposure to the US healthcare market.

Medtronic plc maintains its position as one of the world's leading medical device companies, focusing on therapies that address chronic diseases. The company reported fiscal 2026 second-quarter results in February 2026, with revenue of $8.4 billion, up 4.4% year-over-year on a reported basis and 5.1% organic growth, according to Medtronic press release as of 02/18/2026. This performance underscores its resilience amid healthcare sector dynamics.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Medtronic plc
• Sector/industry: Medical Devices
• Headquarters/country: Dublin, Ireland
• Core markets: US, Europe, Asia
• Key revenue drivers: Cardiovascular, diabetes care, neuromodulation
• Home exchange/listing venue: New York Stock Exchange (NYSE: MDT)
• Trading currency: USD

Medtronic plc: core business model

Medtronic plc develops, manufactures, and sells a wide range of medical devices and therapies. Its portfolio spans four main segments: Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio, and Diabetes. The company emphasizes minimally invasive therapies and patient monitoring solutions. Headquartered in Dublin, Ireland, since its 2015 inversion, Medtronic generates the majority of its revenue from the US market, making it highly relevant for American investors tracking healthcare innovation.

The business model relies on research and development investment, with $1.2 billion spent in the first half of fiscal 2026, representing about 7% of revenue, per the company's Q2 report published February 18, 2026. Medtronic serves over 75 million patients annually through its products, leveraging a global distribution network and partnerships with healthcare providers.

Main revenue and product drivers for Medtronic plc

Cardiovascular products, including pacemakers, defibrillators, and structural heart devices, account for roughly 35% of revenue. The EverPulse portfolio and Hugo robotic-assisted surgery system are key growth drivers. In Q2 fiscal 2026, cardiovascular revenue grew 6.1% organically. Diabetes revenue, driven by MiniMed insulin pumps and continuous glucose monitoring, rose 10.1% in the same period, according to Medtronic as of 02/18/2026.

Neuroscience and surgical segments contribute through spinal implants, ENT devices, and neuromodulation therapies like deep brain stimulation for Parkinson's. These areas benefit from aging population trends and elective procedure recovery post-pandemic. US market penetration remains strong, with Medicare coverage supporting adoption.

Industry trends and competitive position

The medical device industry faces tailwinds from rising chronic disease prevalence and technological advancements like AI integration in diagnostics. Medtronic holds a top-three position globally, competing with Abbott Laboratories, Boston Scientific, and Stryker. Its scale enables R&D leadership, with over 50,000 employees worldwide. In the US, Medtronic's devices are integral to hospital systems, per S&P Global market share data as of 2025.

Why Medtronic plc matters for US investors

Listed on the NYSE under ticker MDT, Medtronic offers US investors direct exposure to the $500 billion US medical device market, which represents about 40% of global demand. The company's revenue from the US exceeded 45% in recent fiscal years, tying its performance to American healthcare spending and policy changes like Medicare reimbursement rates. Its dividend yield, consistently above 3%, appeals to income-focused portfolios amid market volatility.

Conclusion

Medtronic plc demonstrates steady growth through its diversified medical device portfolio and innovation pipeline. Recent quarterly results highlight strength in diabetes and cardiovascular segments, with ongoing investments positioning it for long-term healthcare trends. US investors benefit from its dominant market role and NYSE listing, though sector risks like regulatory scrutiny persist. The company's track record supports its status as a key player in medtech.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.